(Health-NewsWire.Net, May 20, 2016 ) Publisher's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016', provides an overview of the Pancreatic Ductal Adenocarcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma - The report reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pancreatic Ductal Adenocarcinoma therapeutics and enlists all their major and minor projects - The report assesses Pancreatic Ductal Adenocarcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001239342/buying
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001239342/sample
Table of Content: An Overview
Introduction 9 Publisher Report Coverage 9 Pancreatic Ductal Adenocarcinoma Overview 10 Therapeutics Development 11 Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 11 Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 12 Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 13 Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 15 Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 19 Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 21 Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 BerGenBio AS 23 Celgene Corporation 24
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001239342/discount
Clovis Oncology, Inc. 25 Coare Biotechnology, Inc. 26 Concordia Healthcare Corp. 27 FibroGen, Inc. 28 Forty Seven Inc. 29 Gilead Sciences, Inc. 30 Halozyme Therapeutics, Inc. 31 Immodulon Therapeutics Ltd. 32 Immunomedics, Inc. 33 Incuron, LLC 34 Incyte Corporation 35 Inovio Pharmaceuticals, Inc. 36 MedImmune, LLC 37 Medisyn Technologies, Inc. 38 Merck & Co., Inc. 39 Nerviano Medical Sciences S.r.l. 40 OncoMed Pharmaceuticals, Inc. 41 Oryx GmbH & Co. KG 42 Sillajen Biotherapeutics 43 Tara Immuno-Oncology Therapeutics LLC 44 Tokai Pharmaceuticals, Inc. 45 Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001239342/buy/2000
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|